Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after high-intensity chemotherapy or radiation.
Allogeneic stem cell transplantation is used to cure some patients who:
Allogeneic stem cell transplantation can be a high-risk procedure. The high-conditioning regimens are meant to severely or completely impair your ability to make stem cells and you will likely experience side effects during the days you receive high-dose conditioning radiation or chemotherapy. The goals of high-conditioning therapy are to:
The immune system and the blood system are closely linked and can't be separated from each other. Because of this, allogeneic transplantation means that not only the donor's blood system but also his or her immune system is transferred. As a result, these adverse effects are possible:
The immune reaction, or GVHD, is treated by administering drugs to the patient after the transplant that reduce the ability of the donated immune cells to attack and injure the patient's tissues.SeeGraft Versus Host Disease.
Allogeneic stem cell transplants for patients who are older or have overall poor health are relatively uncommon. This is because the pre-transplant conditioning therapy is generally not well tolerated by such patients, especially those with poorly functioning internal organs. However,reduced intensity allogeneic stem cell transplantsmay be an appropriate treatment for some older or sicker patients.
One goal of allogeneic stem cell transplant is to cause the T lymphocytes in the donor's blood or marrow to take hold (engraft) and grow in the patient's marrow. Sometimes the T lymphocytes attack the cancer cells. When this happens, it's called graft versus tumor (GVT) effect (also called graft versus cancer effect). The attack makes it less likely that the disease will return. This effect is more common in myeloid leukemias than it is in other blood cancers.
Unfortunately, T lymphocytes are the same cells that causegraft versus host disease(GVHD). Because of this serious and sometimes life-threatening side effect, doctors in certain cases want to decrease the number of T lymphocytes to be infused with the stem cells. This procedure, called T-lymphocyte depletion, is currently being studied by researchers. The technique involves treating the stem cells collected for transplant with agents that reduce the number of T lymphocytes.
The aim of T-lymphocyte depletion is to lessen GVHD's incidence and severity. However, it can also cause increased rates of graft rejection, a decreased GVT effect and a slower immune recovery. Doctors must be careful about the number of T lymphocytes removed when using this technique.
Stem cell selection is another technique being studied in clinical trials that can reduce the number of T lymphocytes that a patient receives. Because of specific features on the outer coat of stem cells, doctors can selectively remove stem cells from a cell mixture. This technique produces a large number of stem cells and fewer other cells, including T lymphocytes.
If you're considering allogeneic stem cell transplantation, you'll need a bone marrow donor. First, you and your siblings, if any, will have your blood or a scraping from your inside cheek tested to determine tissue type. A sibling has the potential to match you most closely because you both received your genes from the same parents.
A lab technician examines the surface of the sample tissue cells to identify the proteins that give everyone his or her own unique tissue type, called human leukocyte antigens (HLAs). If the HLA on the donor cells are identical (from identical twins, for example) or similar (such as those from siblings), the transplant is more likely to be successful. On average, you have a one in four chance of having the same HLA type as a sibling. Many patients, therefore, don't have a sibling with the same tissue type.
If a brother or sister doesn't provide a match, your doctor will search registries of volunteer donors such as theNational Marrow Donor Programfor an unrelated donor that matches your tissue type. A donor who's not related to you but who has a similar tissue type is called a matched unrelated donor (MUD).
Stem cells for transplantation are collected from three sources:
Before stem cells are collected from blood or bone marrow, the donor must undergo a thorough physical exam and blood testing for hepatitis viruses, human immunodeficiency disease (HIV) and other infectious agents or viruses.
The most common source of stem cells for transplant is peripheral blood, the blood that flows throughout our veins and arteries.
Bone marrow normally releases a small number of peripheral blood stem cells (PBSCs) into the bloodstream. To obtain enough PBSCs for a transplant, the donor takes a white cell growth factor, such as granulocyte-colony stimulating factor (G-CSF) drug, which increases the number of stem cells by drawing them out of the marrow and into the bloodstream. When a patient's own stem cells are used, both G-CSF and the chemotherapy used to treat the disease usually increase PBSCs. In patients who have myeloma and non-Hodgkin lymphoma, the drug plerixafor (Mozobil) can be used to mobilize their own stem cells.
The blood is removed from the donor and the cells collected using a process called apheresis, which involves placing a needle in the donor's vein, usually in the arm, similar to administering a blood test. The donor's blood is pumped through an apheresis machine, which separates the blood into four components: red cells, plasma, white cells and platelets. The white cells and platelets, which contain the stem cells, are collected, while the red cells and plasma are returned to the donor. It can take one to two sessions of apheresis to collect enough blood from a MUD. If you are your own donor, it may take more than two sessions.
If enough stem cells can't be retrieved from apheresis, they can be removed directly from the bone marrow. This requires the donor to undergo a minor outpatient surgical procedure.
While the donor is under anesthesia, the surgeon inserts a hollow needle into the donor's pelvic bones just below the waist and removes liquid marrow. This is done a number of times until several pints of marrow are collected. The donor can expect to stay in the hospital for six to eight hours after the procedure to recover from the anesthesia and the acute pain at the needle insertion sites. He or she may feel some lower back soreness for a few days afterward. The donor's body naturally replaces the marrow soon after the procedure. Red cells are also removed, and the donor may experience anemia, which is often treated with iron supplements.
The marrow that's removed (harvested) passes through a series of filters to remove bone or tissue fragments and is then placed in a plastic bag from which it can be infused into the recipient's vein. The marrow is usually given to the patient within a few hours and almost always within 24 hours. If necessary, however, marrow can be frozen and stored and will remain suitable for use for years. If the transplant is autologous, the marrow is usually frozen while the patient undergoes intensive chemotherapy.
A rich source of stem cells for blood cancer patients are the stored stem cells collected from the umbilical cord and placenta after a baby is born, called the cord blood unit. Parents may choose to have the cord blood unit collected after delivery. Healthy parents with healthy children and no transplant candidate in the family can choose to donate their newborn's cord blood to cord blood banks or research programs at participating hospitals. Parents with a child or a family member who could be a candidate for transplantation should discuss with their doctor the potential benefits of saving their newborn's cord blood for possible family use.
Advantages of Using Cord Blood
The advantages of using cord blood stem cells instead of donor peripheral blood or donor marrow stem cells include:
Disadvantages of Using Cord Blood
There can be disadvantages of using cord blood stem cells as well:
The decrease in marrow function often begins to take effect by the second or third day after an allogeneic stem cell infusion. You'll be kept in a protected environment to reduce contact with infectious agents. Generally within two to four weeks after the transplant, the engraftment of donated cells will be apparent from the appearance of normal white cells in your blood. You'll receive periodic transfusions of red cells and platelets until your marrow function has been restored by the transplanted stem cells.
Your doctor will carefully monitor you with physical exams, blood chemistry tests, imaging studies and other tests to ensure that your heart, lungs, kidneys, liver and other major organs are functioning normally. You'll need drugs to prevent GVHD, in addition to blood transfusions. If you're suffering from a poor appetite or diarrhea, you may need to be fed intravenously or through a duodenal tube (called hyperalimentation) to ensure you get adequate nutrition.
Continue reading here:
Allogeneic Stem Cell Transplantation | Leukemia and ...
- Crispr's next frontier is in-human treatment, says co-inventor - The Business Times - October 21st, 2019
- Damien Cook confident that Sam Burgess will continue playing despite shoulder injury - Sporting News AU - October 21st, 2019
- Teen Cancer Survivor uses Haunted House to Help Others Fight - WFMYNews2.com - October 21st, 2019
- Five ways fasting can help in the fight against cancer - The Standard - October 21st, 2019
- Brooks Koepka Withdraws in Korea After Reaggravating Knee Injury - Golf Channel - October 19th, 2019
- Injured Williamson to miss start of season | Sports | Journal Gazette - Fort Wayne Journal Gazette - October 19th, 2019
- New Gene Therapy Approach Reduces Cost and Improves Efficiency - DocWire News - October 19th, 2019
- StemSpine to Launch in the United States Following Successful Treatments Overseas with 12+ Months Data Showing Safety and Efficacy (CELZ) - Stock Day... - October 19th, 2019
- Stem cells treatment gives hope in fighting Autism, blood disorders - OrissaPOST - October 19th, 2019
- The 'Magic' Behind Every Successful Blockbuster Drug - DailyWealth - October 19th, 2019
- Synthetic presentation of noncanonical Wnt5a motif promotes mechanosensing-dependent differentiation of stem cells and regeneration - Science Advances - October 17th, 2019
- The Prognostic Importance of EVI1 Expression - Cancer Network - October 17th, 2019
- Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 - ResearchAndMarkets.com - Business Wire - October 17th, 2019
- ROOT OF SKIN Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan - Associated Press - October 17th, 2019
- The global T-cell therapy market size is expected to reach USD 7.51 billion, expanding at a CAGR of 15.4% by 2026 - Yahoo Finance - October 17th, 2019
- Sarah Ferguson opens up about years of plastic surgery from Botox to fillers to stem cell therapy - Evening Standard - October 17th, 2019
- Targeting CCR5 trafficking to inhibit HIV-1 infection - Science Advances - October 17th, 2019
- The Afterlife of Afterbirth - MedPage Today - October 15th, 2019
- Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenstrm Macroglobulinemia - Cancer Therapy Advisor - October 15th, 2019
- Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress - Business Wire - October 15th, 2019
- Equine Medical Research Funding Receives USEA Board of Governors - United States Eventing Association - October 15th, 2019
- ROOT OF SKIN Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan - PRNewswire - October 15th, 2019
- Joy as funding rises for Moscow treatment trip - Northern Times - October 15th, 2019
- Sarah Ferguson reveals highlight of my life as she celebrates 60th birthday - Express - October 15th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Is Segmented On The Basis Of Product, Technology And End User 2026 - Statsflash - October 15th, 2019
- Second annual Regenerative Medicine summit proves big win for The Bahamas - EyeWitness News - October 15th, 2019
- UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon - TechCrunch - October 15th, 2019
- Ridgefield woman, her mother write book about battle with MS - The Columbian - October 15th, 2019
- How the bodys cells can prevent the need for surgery - ABC 4 - October 15th, 2019
- ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases - Proactive... - October 15th, 2019
- Gay Couple Adopt HIV-Positive Child After She Was Rejected By Ten Other Families - UNILAD - October 15th, 2019
- Coming Unstuck and Reaching Beyond Ourselves - ALS News Today - October 13th, 2019
- Cody Garbrandt looking at a March start for road back to the top - MMA Mania - October 13th, 2019
- Exclusive Growth Report on Animal Stem Cell Therapy Market 2019 Increasing Demand with Leading Key Players: J-ARM,U.S. Stem Cell,Celavet Inc. - Pledge... - October 13th, 2019
- Sarah Ferguson gets candid on using Botox, laser facelifts and stem cell therapy for her feet - Fox News - October 12th, 2019
- Drexel on the Road: Stem cell study for osteoarthritis - WKRG News 5 - October 12th, 2019
- Sarah Ferguson was in pain during Eugenies wedding - and needed treatment to recover - Express - October 12th, 2019
- Jazz plays itself into cell therapy - Vantage - October 12th, 2019
- Gnaw on the Remake of David Cronenberg's 'Rabid' This December [Trailer] - Bloody Disgusting - October 12th, 2019
- Advanced Research Report on Animal Stem Cell Therapy Market 2019 Potentially Growing Significant Business Opportunities with top companies U.S. Stem... - October 12th, 2019
- Stem Cell Therapy Market 2019: Prosperous Growth, Recent Trends and Demand by Top Key Vendors like Osiris Therapeutics, MEDIPOST Co., Anterogen Co.,... - October 12th, 2019
- BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - TimminsToday - October 10th, 2019
- Golf: Brooks Koepka healthy again after stem cell treatment but game rusty - The Straits Times - October 10th, 2019
- New Viral Vector for Sickle Cell Gene Therapy Likely to Be More Effective, NIH Study Says - Sickle Cell Anemia News - October 10th, 2019
- R3 Stem Cell Announces Addition of World Renowned Exosome Expert Dr. Ian White to Training Course - Yahoo Finance - October 10th, 2019
- Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)(i) - Canada NewsWire - October 10th, 2019
- Novo Nordisk and bluebird bio Enter 3-Year Gene Therapy Collaboration Pact - BioSpace - October 10th, 2019
- Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected... - October 10th, 2019
- Caroline Wyatt: The fight to reverse damage caused by MS - BBC News - October 10th, 2019
- AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis - Business Wire - October 10th, 2019
- We believe we can stop MS, and this is how - Metro.co.uk - October 10th, 2019
- Brooks Koepka had stem cell treatment on knee during offseason - ESPN - October 4th, 2019
- Early clinical trial for ALS sufferers shows biotech firm 'on the right track' - The Times of Israel - October 4th, 2019
- "I have talked about this treatment for so long... I finally gave in and set up the GoFundMe page. It killed me to have to do it." - Echo... - October 4th, 2019
- Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) - Markets Gazette - October 4th, 2019
- Brooks Koepka Reveals He Had Stem Cell Treatment on Knee Injury in PGA Offseason - Bleacher Report - October 3rd, 2019
- Michael Schumacher health latest: What is stem cell therapy and how will it help Schumi? - Express.co.uk - October 3rd, 2019
- Exploring the Latest in CRISPR and Stem Cell Research - Technology Networks - October 3rd, 2019
- AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company's Platform Immunotherapy -... - October 3rd, 2019
- Improved Gene Therapy in Sickle Cell Disease - Technology Networks - October 3rd, 2019
- Biochemistry Graduate is the Researcher's Researcher at Advanced BioCatalytics - AroundtheO - October 3rd, 2019
- Pike families to enter part of mine day before widow's cancer treatment begins - Stuff.co.nz - October 3rd, 2019
- Adcetris May Be Effective in Heavily Pre-Treated Hodgkin's Cases, Study Shows - Lymphoma News Today - October 3rd, 2019
- Warwick mum's fundraising ball to help fund 50000 treatment to fight the progression of MS - Warwick Courier - October 3rd, 2019
- Bone marrow donor registry pleas for more diversity to help save people with cancer - ABC News - October 3rd, 2019
- I hope treatment will stop Multiple Sclerosis in its tracks - Echo Live - October 3rd, 2019
- Stem Cell Therapy Market Synthesis and Opportunity Assessment 2019-2024 - Markets Gazette - October 3rd, 2019
- R3 Stem Cell Launches Master Class Series on Stem Cell Therapy and Regenerative Medicine - PRNewswire - October 1st, 2019
- ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center -... - October 1st, 2019
- Michael Schumachers surgeon denies hes performing experiments on F1 legend with stem cell treatment and sl - The Sun - October 1st, 2019
- Regenerative Stem Cell Therapy Pioneer, Celavie Biosciences, LLC, to Attend Cell & Gene Meeting on the Mesa on October 2 4 in Carlsbad,... - October 1st, 2019
- Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in... - October 1st, 2019
- The Shocking Culture of Nurses and the Treatment of Patients with Sickle Cell - Nurse.org - October 1st, 2019
- CBMG: Initiating Coverage of Cellular Biomedicine Group; Multiple Cell-Based Therapies to Treat Cancer and Degenerative Diseases - Zacks Small Cap... - October 1st, 2019
- Brestoff, Theunissen recognized by NIH for innovative research - Washington University School of Medicine in St. Louis - October 1st, 2019
- Major Talent Acquisition Takes Montreal-Based Morphocell Technologies to the Next Level - BioSpace - October 1st, 2019
- Lineage Cell Therapeutics to Present New OpRegen Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019 - Business Wire - October 1st, 2019
- Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem... - October 1st, 2019
- VetStem Biopharma Shares the Success Story of Cheyenne Who Was Treated with VetStem Cell Therapy by Dr. Scott Reiners - PR Web - October 1st, 2019
- Manav Rachna International Institute of Research and Studies, Faridabad and Advancells Announce Industry-Academia, Noida - Business Wire India - October 1st, 2019